CA2177257A1 - Condensation polymer of an aromatic sulfonic acid and an aldehyde for inhibiting hiv infectivity - Google Patents

Condensation polymer of an aromatic sulfonic acid and an aldehyde for inhibiting hiv infectivity

Info

Publication number
CA2177257A1
CA2177257A1 CA002177257A CA2177257A CA2177257A1 CA 2177257 A1 CA2177257 A1 CA 2177257A1 CA 002177257 A CA002177257 A CA 002177257A CA 2177257 A CA2177257 A CA 2177257A CA 2177257 A1 CA2177257 A1 CA 2177257A1
Authority
CA
Canada
Prior art keywords
aldehyde
aids
compounds
aromatic sulfonic
sulfonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002177257A
Other languages
French (fr)
Other versions
CA2177257C (en
Inventor
Shyam K. Singh
Raymond J. Patch
Peter V. Pallai
Edith A. Neidhardt
Gerard P. Palace
Kevin J. Willis
Theresa M. Sampo
Kevin W. Mcdonald
Zhan Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Pharmaceuticals Solutions Inc
Original Assignee
Shyam K. Singh
Raymond J. Patch
Peter V. Pallai
Edith A. Neidhardt
Gerard P. Palace
Kevin J. Willis
Theresa M. Sampo
Kevin W. Mcdonald
Zhan Shi
Procept, Inc.
Heavenlydoor.Com, Inc.
Paligent Inc.
Indevus Pharmaceuticals, Inc.
Endo Pharmaceuticals Solutions Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shyam K. Singh, Raymond J. Patch, Peter V. Pallai, Edith A. Neidhardt, Gerard P. Palace, Kevin J. Willis, Theresa M. Sampo, Kevin W. Mcdonald, Zhan Shi, Procept, Inc., Heavenlydoor.Com, Inc., Paligent Inc., Indevus Pharmaceuticals, Inc., Endo Pharmaceuticals Solutions Inc. filed Critical Shyam K. Singh
Publication of CA2177257A1 publication Critical patent/CA2177257A1/en
Application granted granted Critical
Publication of CA2177257C publication Critical patent/CA2177257C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD4 cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV
infection. The compounds can also be used to treat blood preparations.
CA002177257A 1993-11-23 1994-11-17 Condensation polymer of an aromatic sulfonic acid and an aldehyde for inhibiting hiv infectivity Expired - Fee Related CA2177257C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15644393A 1993-11-23 1993-11-23
US08/156,443 1993-11-23
US08/245,619 1994-05-19
US08/245,619 US5614559A (en) 1993-11-23 1994-05-19 Compound for inhibiting HIV infectivity
PCT/US1994/013335 WO1995014479A1 (en) 1993-11-23 1994-11-17 Condensation polymer of an aromatic sulfonic acid and an aldehyde for inhibiting hiv infectivity

Publications (2)

Publication Number Publication Date
CA2177257A1 true CA2177257A1 (en) 1995-06-01
CA2177257C CA2177257C (en) 2007-09-25

Family

ID=26853188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177257A Expired - Fee Related CA2177257C (en) 1993-11-23 1994-11-17 Condensation polymer of an aromatic sulfonic acid and an aldehyde for inhibiting hiv infectivity

Country Status (11)

Country Link
US (4) US5614559A (en)
EP (1) EP0730462B1 (en)
JP (1) JP3866280B2 (en)
AT (1) ATE297743T1 (en)
AU (1) AU1181795A (en)
CA (1) CA2177257C (en)
DE (1) DE69434407T2 (en)
DK (1) DK0730462T3 (en)
ES (1) ES2244961T3 (en)
PT (1) PT730462E (en)
WO (1) WO1995014479A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614559A (en) 1993-11-23 1997-03-25 Procept Inc. Compound for inhibiting HIV infectivity
CA2190304A1 (en) * 1995-12-15 1997-06-16 Elazar Rabbani Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
US5958399A (en) * 1997-05-01 1999-09-28 Procept, Inc. Sulfonic acid and aldehyde condensation polymers for preventing pregnancy
US6290946B1 (en) * 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6270755B1 (en) 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
US20030104635A1 (en) * 1999-09-21 2003-06-05 Avidex Limited Screening methods
GB9922352D0 (en) * 1999-09-21 1999-11-24 Avidex Ltd Screening method
CA2314494A1 (en) 2000-05-02 2001-11-02 Geltex Pharmaceuticals, Inc. Anionic polymers as species specific antibacterial agents
AU2001281747A1 (en) * 2000-08-02 2002-02-13 H:S Hvidovre Hospital Composition and method for the treatment or prevention of hiv infection
WO2002064154A2 (en) * 2001-02-15 2002-08-22 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inhibiting hiv-coreceptor interactions
WO2003082193A2 (en) * 2002-03-26 2003-10-09 Eastern Virginia Medical School Suramin and derivatives thereof as topical microbicide and contraceptive
WO2004009100A1 (en) * 2002-07-22 2004-01-29 Genzyme Corporation Poly (potassium and sodium styrene sulfonate), its manufacture and its uses
US7451064B2 (en) * 2004-10-06 2008-11-11 Hewlett-Packard Development Company, L.P. System and method for logging hardware usage data, and uses for such logged hardware usage data
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
CA2583666A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
CN101918008B (en) 2007-11-14 2014-07-30 巴斯夫欧洲公司 Condensation products based on bicyclic or polycyclic aromatic or heteroaromatic compounds
US8604086B2 (en) * 2008-02-27 2013-12-10 Endo Pharmaceuticals Solutions Inc. Sulfonic acid and aldehyde condensation polymers for the treatment and prevention of HPV
JP2011020993A (en) * 2009-06-16 2011-02-03 Sekisui Chem Co Ltd Rna virus infection-inhibiting molding composition, and rna virus infection-inhibiting molded article
WO2023051923A1 (en) 2021-09-30 2023-04-06 Basf Se Polymers obtained by the reacion of a phenolic compound and a carbonyl compound as anti-sars-cov-2 agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167344A (en) * 1977-07-01 1979-09-11 Morley Studios Electronically controlled token engraving apparatus
US4361547A (en) * 1980-07-25 1982-11-30 Johnson & Johnson Products, Inc. Sulfonated aromatic formaldehyde condensation polymers as dental plaque barriers
US4362712A (en) * 1980-07-25 1982-12-07 Johnson & Johnson Products, Inc. Carboxylated naphthalene formaldehyde condensation polymers as dental plaque barriers
US4403089A (en) * 1980-07-25 1983-09-06 Johnson & Johnson Products, Inc. Carboxylated naphthalene formaldehyde condensation polymers as dental plaque barriers
US4364927A (en) * 1980-07-25 1982-12-21 Johnson & Johnson Products, Inc. Sulfonated naphthalene formaldehyde condensation polymers as dental plaque barriers
US4432967A (en) 1982-06-25 1984-02-21 National Starch And Chemical Corp. Contraceptive composition
GB8327562D0 (en) * 1983-10-14 1983-11-16 Ici Plc Contraceptive methods
US4604404A (en) * 1985-04-03 1986-08-05 A. H. Robins Company, Inc. Antiviral sulfonated naphthalene formaldehyde condensation polymers
US5177083A (en) * 1986-07-03 1993-01-05 The Scripps Clinic And Research Foundation Drugs effective against retroviruses
DE3734189A1 (en) * 1987-10-09 1989-04-27 Hoechst Ag METHOD FOR SEPARATING AND RECOVERING NAPHTHALINSULPHONIC ACIDS FROM AQUEOUS SOLUTIONS
NL8900442A (en) * 1989-02-22 1990-09-17 Stichting Rega V Z W SULFATED VINYL POLYMERS IN MEDICINES FOR TREATING RETROVIRUS INFECTIONS.
FR2669535A1 (en) * 1990-11-26 1992-05-29 Medgenix Group Sa Use of polysulphonated macromolecules as a medicament
US5312837A (en) * 1991-01-29 1994-05-17 Genelabs Technologies, Inc. Method of treating viral infections with aryl macrocyclic compounds
US5424063A (en) * 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process
WO1994003164A1 (en) * 1992-08-06 1994-02-17 Genelabs Technologies, Inc. Inhibition and treatment of infection by enveloped virus with calix(n) arene compounds
US5308612A (en) * 1992-08-12 1994-05-03 Blue Marble Research, Inc. Uses of polystyrenesulfonate and related compounds as inhibitors of transactivating transcription factor (TAT) and as therapeutics for HIV infection and AIDS
WO1994014763A1 (en) * 1992-12-23 1994-07-07 Procept, Inc. Novel agents for inhibition of hiv infectivity and use therefor
US5614559A (en) * 1993-11-23 1997-03-25 Procept Inc. Compound for inhibiting HIV infectivity
WO1996028169A1 (en) * 1995-03-15 1996-09-19 Medical College Of Hampton Roads Glycoconjugate inhibitors of human sperm-egg binding

Also Published As

Publication number Publication date
CA2177257C (en) 2007-09-25
ES2244961T3 (en) 2005-12-16
WO1995014479A1 (en) 1995-06-01
PT730462E (en) 2005-11-30
ATE297743T1 (en) 2005-07-15
DE69434407T2 (en) 2006-03-16
US6075050A (en) 2000-06-13
JPH09510687A (en) 1997-10-28
DK0730462T3 (en) 2005-10-17
JP3866280B2 (en) 2007-01-10
AU1181795A (en) 1995-06-13
US5614559A (en) 1997-03-25
US5677343A (en) 1997-10-14
EP0730462A1 (en) 1996-09-11
EP0730462B1 (en) 2005-06-15
US6365625B1 (en) 2002-04-02
DE69434407D1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
CA2177257A1 (en) Condensation polymer of an aromatic sulfonic acid and an aldehyde for inhibiting hiv infectivity
Chang et al. Differential inhibition of reverse transcriptase and cellular DNA polymerase-α activities by lignans isolated from Chinese herbs, Phyllanthus myrtifolius Moon, and tannins from Lonicera japonica Thunb and Castanopsis hystrix
Tochikura et al. Inhibition (in vitro) of replication and of the cytopathic effect of human immunodeficiency virus by an extract of the culture medium of Lentinus edodes mycelia
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
EP0301570A3 (en) Oligopeptides useful for treating aids
CA2082825A1 (en) Inhibition of viral infection
TW354792B (en) Olefin polymerization catalyst and process for preparing polypropylene and propylene block copolymer
WO1997020554B1 (en) Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc
CA2022539A1 (en) Albumin derivatives with therapeutic functions
CA2107732A1 (en) Retrovirus from the hiv group and its use
NO870053D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE, NITROGENIC, CONDENSED, AROMATIC COMPOUNDS.
DE3853779T2 (en) HIV-1 NEUTRALIZING MONOCLONAL ANTIBODIES.
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
DE69106493T2 (en) Sulfonic stilbene derivatives for the treatment of viral diseases.
EP0225066A3 (en) Antigen determinant peptides and a process for the preparation thereof
NO983435L (en) Disclosed are
WO2001078648A3 (en) 6-methylnicotinamide derivatives as antiviral agents
CA2195125A1 (en) Difluorostatone antiviral agents
WO1990013281A3 (en) Method of suppressing hiv infection
CA2155020A1 (en) Antiviral naphthoquinone compounds, compositions and uses thereof
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
CA2114859A1 (en) Cytotoxic and antiviral compound
CA2027276A1 (en) Novel .alpha.-glucosidase inhibitors
ATE94760T1 (en) SULPHATED VINYL POLYMERS IN PREPARATIONS FOR THE TREATMENT OF RETROVIRAL INFECTIONS.
Chang et al. Dextran sulfate as an inhibitor against the human immunodeficiency virus

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141117